Temasek joins US$150m funding for US biotech firm

Orchard Therapeutics will utilise the funding to register and commercialise their clinical programs.

Temasek joined the US$150m Series C financing led by New York-based hedge fund sponsor Deerfield Management for US biotech firm Orchard Therapeutics, an announcement revealed.

“We are pleased to have led this round of financing. We believe the company has generated compelling clinical data on products which have the potential to become breakthrough treatments for patients,” Deerfield Management principal Elise Wang said.

Orchard Therapeutics will utilise the fund in order for the firm’s advanced clinical programs to approach registration and commercialization. The completed deal will also back the clinical and preclinical development of the company’s rare disease gene therapy pipeline.

“We are advancing our pipeline of potentially transformative gene therapies in primary immune deficiencies and neurometabolic disorders to reach patients as quickly as possible,” Orchard CFO and cheif business officer Frank Thomas commented.

The firm holds offices in London, San Francisco, and Boston.

Also Read

Gazelle Ventures offers to acquire No Signboard shares at $0.0021 apiece

Moomoo, Nasdaq renew global strategic partnership

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit